. 2023 Oct 17;15(20):4396. doi: 10.3390/nu15204396

Table 3.

Effect of Zn supplementation on mental status after 12 weeks of intervention.

	Group	Adjusted Mean	CI 95%	Δ	CI 95% Δ	p-Value
MMSE	Placebo	27.57	(26.91–28.24)	0.885 *	(0.03–1.74)	0.044 *
MMSE	Zinc	28.46	(27.95–28.97)	0.885 *	(0.03–1.74)	0.044 *
VFT	Placebo	21.23	(19.23–23.24)	0.877	(−1.69–3.44)	0.490
VFT	Zinc	22.11	(20.57–23.65)	0.877	(−1.69–3.44)	0.490
Clock Test	Placebo	9.20	(8.76–9.64)	0.283	(−0.27–0.84)	0.306
Clock Test	Zinc	9.48	(9.14–9.82)	0.283	(−0.27–0.84)	0.306
Stroop test ^a	Placebo	68.13	(64.39–71.87)	−6.156	(−10.90–−1.42)	0.013 *
Stroop test ^a	Zinc	61.97	(59.08–64.86)	−6.156	(−10.90–−1.42)	0.013 *
BDI-II ^a	Placebo	12.86	(9.85–15.88)	2.276	(1.89–0.24)	0.239
BDI-II ^a	Zinc	15.14	(12.80–17.48)	2.276	(1.89–0.24)	0.239
Beck scale ^a	Placebo	12.59	(7.08–18.10)	−2.340	(−9.37–4.69)	0.500
Beck scale ^a	Zinc	10.25	(5.95–14.55)	−2.340	(−9.37–4.69)	0.500

Data corrected for baseline. Analysis of covariance (ANCOVA) used to test post-test differences between groups. Δ Difference between the post-test between the groups. CI 95% p < 0.05 considered significant. Mini-mental state examination (MMSE). Verbal fluency test (VFT). Beck depression inventory (BDI-II). ^a A higher score indicates a worse performance. * p < 0.05.